Sotrovimab No Longer Authorized for COVID-19 Treatment in Some Regions

3/25/22 — The FDA has rescinded EUA for sotrovimab to treat COVID-19 in HHS Regions 1 and 2 because the authorized dose is unlikely to be effective against the Omicron BA.2 sub-variant. CDC Nowcast data estimates that, as of March 19, 2022, the BA.2 sub-variant accounts for more than 50 percent of COVID-19 cases in these regions. HHS Regions 1 and 2 include the following states and territories: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Puerto Rico, and the Virgin Islands. Read the FDA EUA update. Read the revised FDA fact sheet for healthcare providers for sotrovimab.